Idag, fredag 30 augusti, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv2 2024...
The NTAP reimbursement decision is distinctly positive, and the CMS decision enables clinics to use ...
En väsentlig osäkerhetsfaktor om hur stort det avslutade högvolymprogrammet var har nu lyfts från ak...
Ett starkt kvartal till: Depåstoppsmodellen lyfte omsättningen kraftigt, +24%, och resultatet ökade ...
Redeye return with a research update following BioArctic's Q2 report and recent events, and largely ...
Redeye comments on Ngenic’s Q2 report, which presented a y-o-y decline in both net sales and profita...
Redeye saw sales that were markedly above and results that were in line with our expectations.
Redeye updates its view on Xbrane following a Q2 report hinting at accelerating sales but also highl...
Redeye returns with a more detailed take on the Q1 report.
Redeye updates on GiG following Q2-results which were overall close to our expectations and full foc...
Sprint Bioscience has Q2 sales of SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balanc...
Northbaze announced yesterday the acquisition of Enter Sales & Distribution AB, a company with three...
Product sales (+13% y-o-y) and new billings (+12%) with the strongest growth rates in 2 years Uncert...
Q2 challenging, same trends expected for Q3 Paper — better demand, more supply cuts, higher prices F...
ODI Pharma published on August 29th the company’s Q4-report for 2023/2024, which showed a continued ...
Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue tha...
Redeye comments on Lytix’ second quarter report 2024.
Redeye is pleased that Lifeclean is getting some traction on its efforts in the PFAS area.
AcuCort AB (”AcuCort” eller ”Bolaget”) har presenterat en Q2-rapport där mycket kretsar kring den st...
Solid sales growth (14% y-o-y) and positive FCF EBIT estimates down slightly on higher opex in Q2 7-...
